Abstract
Purpose
Mesenchymal–epithelial transition (MET) amplification is one of the mechanisms accounting for the resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung cancer patients, as well as the poor prognosis. Fluorescence in situ hybridization (FISH) is the most widely used method for MET amplification detection. However, it is inapplicable when tissue samples were unavailable. Herein, we assessed the value of droplet digital PCR (ddPCR) in MET copy number gain (CNG) detection in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKIs.
Materials and methods
A total of 103 cancer tissues and the paired peripheral blood samples from NSCLC patients were collected for MET CNG detection using ddPCR. In parallel, MET amplification in tissue samples was verified by FISH. Also, the relationships between MET CNG and EGFR T790M, as well as the EGFR-TKI resistance were also evaluated using Chi-square or Fisher’s exact tests.
Result
The concordance rate of ddPCR and FISH in detecting MET CNG in tissue samples was 100% (102/102), and it was 94.17% (97/103) for ddPCR method in detecting the MET CNG among peripheral blood and tissue samples. No statistical difference was observed between MET amplification and EGFR T790M (p = 0.65), while MET amplification rate was significantly increased in patients with resistance to third generations of EGFR-TKIs as compared with patients with resistance to first/second EGFR-TKIs (p < 0.05).
Conclusions
ddPCR is an alternative method to detect MET CNG in both tissues and peripheral blood samples, which is of worthy in clinical promotion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Ahn BC, Lee JH, Kim MH, Pyo KH, Lee CK, Lim SM, Kim HR, Cho BC, Hong MH (2021) Distinct characteristics and clinical outcomes to predict the emergence of MET amplification in patients with non-small cell lung cancer who developed resistance after treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Cancers (basel). https://doi.org/10.3390/cancers13123096
Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M et al (2017) A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Eur J Cancer 87:131–139. https://doi.org/10.1016/j.ejca.2017.10.016
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932–20937. https://doi.org/10.1073/pnas.0710370104
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Camidge DR, Davies KD (2019a) MET copy number as a secondary driver of epidermal growth factor receptor tyrosine kinase inhibitor resistance in EGFR-mutant non-small-cell lung cancer. J Clin Oncol 37:855–857. https://doi.org/10.1200/JCO.19.00033
Castiglione R, Alidousty C, Holz B, Wagener S, Baar T, Heydt C, Binot E, Zupp S, Kron A, Wolf J et al (2019) Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Mod Pathol 32:627–638. https://doi.org/10.1038/s41379-018-0182-8
Cescon DW, Bratman SV, Chan SM, Siu LL (2020) Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer 1:276–290. https://doi.org/10.1038/s43018-020-0043-5
Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA et al (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815. https://doi.org/10.1038/ncomms11815
Chin RI, Chen K, Usmani A, Chua C, Harris PK, Binkley MS, Azad TD, Dudley JC, Chaudhuri AA (2019) Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA). Mol Diagn Ther 23:311–331. https://doi.org/10.1007/s40291-019-00390-5
Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644. https://doi.org/10.1016/j.ccm.2011.09.001
Drilon A, Cappuzzo F, Ou S-HI, Camidge DR (2017) Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol 12:15–26. https://doi.org/10.1016/j.jtho.2016.10.014
Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R et al (2018) MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget 9:12959–12970. https://doi.org/10.18632/oncotarget.24430
Frazzi R, Bizzarri V, Albertazzi L, Cusenza VY, Coppolecchia L, Luminari S, Ilariucci F (2020) Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia. Br J Haematol 189:e49–e52. https://doi.org/10.1111/bjh.16442
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V et al (2016) The IASLC lung cancer staging project: proposals for revision of the tnm stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009
Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR (2018) Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann Oncol 29:1049–1055. https://doi.org/10.1093/annonc/mdy005
Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumours—molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17:569–587. https://doi.org/10.1038/s41571-020-0377-z
Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20:71–88. https://doi.org/10.1038/s41576-018-0071-5
Hieggelke L, Schultheis AM (2020) Application of FISH in the diagnosis of lung cancer. Pathologe 41:582–588. https://doi.org/10.1007/s00292-020-00831-7
Hodkinson BP, Schaffer M, Brody JD, Jurczak W, Carpio C, Ben-Yehuda D, Avivi I, Forslund A, Ozcan M, Alvarez J et al (2021) Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter’s transformation. Transl Oncol 14:100977. https://doi.org/10.1016/j.tranon.2020.100977
Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, Marquette CH, Hofman P (2014) Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2:107. https://doi.org/10.3978/j.issn.2305-5839.2014.08.11
Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K, Nishio K (2014) Targeting MET amplification as a new oncogenic driver. Cancers (basel) 6:1540–1552. https://doi.org/10.3390/cancers6031540
Kinugasa H, Nouso K, Tanaka T, Miyahara K, Morimoto Y, Dohi C, Matsubara T, Okada H, Yamamoto K (2015) Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer 112:1652–1655. https://doi.org/10.1038/bjc.2015.129
Kitazono S, Sakai K, Yanagitani N, Ariyasu R, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S et al (2019) Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Cancer Sci 110:3350–3357. https://doi.org/10.1111/cas.14153
Lai GGY, Lim TH, Lim J, Liew PJR, Kwang XL, Nahar R, Aung ZW, Takano A, Lee YY, Lau DPX et al (2019) Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol 37:876–884. https://doi.org/10.1200/JCO.18.00177
Landi L, Chiari R, Tiseo M, D’Inca F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL et al (2019) Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin Cancer Res 25:7312–7319. https://doi.org/10.1158/1078-0432.CCR-19-0994
Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W et al (2018) Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res 24:6195–6203. https://doi.org/10.1158/1078-0432.CCR-18-1542
Lee M, Jain P, Wang F, Ma PC, Borczuk A, Halmos B (2021) MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Expert Opin Ther Targets 25:249–268. https://doi.org/10.1080/14728222.2021.1925648
Li J, Wang Y, Zhang B, Xu J, Cao S, Zhong H (2020) Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing. Lung Cancer 149:17–22. https://doi.org/10.1016/j.lungcan.2020.08.021
Liao BC, Griesing S, Yang JC (2019) Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol 11:1758835919890286. https://doi.org/10.1177/1758835919890286
Lim SM, Syn NL, Cho BC, Soo RA (2018) Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev 65:1–10. https://doi.org/10.1016/j.ctrv.2018.02.006
Mao X, Zhang Z, Zheng X, Xie F, Duan F, Jiang L, Chuai S, Han-Zhang H, Han B, Sun J (2017) Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. J Thorac Oncol 12:663–672. https://doi.org/10.1016/j.jtho.2016.11.2235
Mikhail FM, Biegel JA, Cooley LD, Dubuc AM, Hirsch B, Horner VL, Newman S, Shao L, Wolff DJ, Raca G (2019) Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). Genet Med 21:1903–1916. https://doi.org/10.1038/s41436-019-0545-7
Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM, Husain H (2019) Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res 79:689–698. https://doi.org/10.1158/0008-5472.CAN-18-1281
Noonan SA, Berry L, Lu X, Gao D, Barón AE, Chesnut P, Sheren J, Aisner DL, Merrick D, Doebele RC et al (2016) Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol 11:1293–1304. https://doi.org/10.1016/j.jtho.2016.04.033
Olmedillas-Lopez S, Garcia-Arranz M, Garcia-Olmo D (2017) Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther 21:493–510. https://doi.org/10.1007/s40291-017-0278-8
Organ SL, Tsao MS (2011) An overview of the c-MET signaling pathway. Ther Adv Med Oncol 3:S7–S19. https://doi.org/10.1177/1758834011422556
Ou S, Pavlick D, Stephens PJ, Ross J, Miller V, Ali S, Schrock A (2017) Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) cases with focal and non-focal MET amplification. J Thorac Oncol 12:S1778–S1779. https://doi.org/10.1016/j.jtho.2017.09.400
Overbeck TR, Cron DA, Schmitz K, RittmeyerKörberHugoSchnalkeLukatHugoHinterthaner AWSJLTM et al (2020) Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Transl Lung Cancer Res 9:603–616. https://doi.org/10.21037/tlcr-19-339
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ et al (2018) Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol 4:1527–1534. https://doi.org/10.1001/jamaoncol.2018.2969
Perdigones N, Murtaza M (2017) Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. Pharmacol Ther 174:22–26. https://doi.org/10.1016/j.pharmthera.2017.02.003
Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y et al (2018) Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 36:841–849. https://doi.org/10.1200/JCO.2017.74.7576
Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 377:849–861. https://doi.org/10.1056/NEJMra1703413
Recondo G, Che J, Janne PA, Awad MM (2020) Targeting MET dysregulation in cancer. Cancer Discov 10:922–934. https://doi.org/10.1158/2159-8290.CD-19-1446
Sacco JJ, Clague MJ (2015) Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance. Transl Lung Cancer Res 4:242–252. https://doi.org/10.3978/j.issn.2218-6751.2015.03.05
Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D et al (2015) Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 33:2667–2674. https://doi.org/10.1200/JCO.2014.60.7317
Schildhaus HU, Schultheis AM, Ruschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M et al (2015) MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 21:907–915. https://doi.org/10.1158/1078-0432.CCR-14-0450
Sequist LV, Han J-Y, Ahn M-J, Cho BC, Yu H, Kim S-W, Yang JC-H, Lee JS, Su W-C, Kowalski D et al (2020) Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol 21:373–386. https://doi.org/10.1016/s1470-2045(19)30785-5
Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL et al (2019) How liquid biopsies can change clinical practice in oncology. Ann Oncol 30:1580–1590. https://doi.org/10.1093/annonc/mdz227
Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, Hayashi S, Sueoka E, Kimura S (2012) Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 75:89–94. https://doi.org/10.1016/j.lungcan.2011.06.004
Tang C, Zhu L, Zhang L, Tan C, Peng Z, Liu B, Liu W, Hu H, Bai Y, Wang B et al (2020) Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients. Clin Chim Acta 510:88–96. https://doi.org/10.1016/j.cca.2020.07.003
Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J et al (2016) Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22:5772–5782. https://doi.org/10.1158/1078-0432.CCR-16-1231
Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH et al (2016) MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res 22:3048–3056. https://doi.org/10.1158/1078-0432.CCR-15-2061
Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834–848. https://doi.org/10.1038/nrm3012
Wang Y, He Y, Tian P, Wang W, Wang K, Chuai S, Li Y, Zhao S, Wang Y, Li W (2020) Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib. Transl Lung Cancer Res 9:1952–1962. https://doi.org/10.21037/tlcr-20-915
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV et al (2020) Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 383:944–957. https://doi.org/10.1056/NEJMoa2002787
Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E et al (2018) Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol 36:3101–3109. https://doi.org/10.1200/JCO.2018.77.7326
Wu S, Li G, Zhao X, Xiang J, Lizaso A, Ye J, Shi C, Chen L (2020) High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy. Ann Transl Med 8:685. https://doi.org/10.21037/atm-20-2741
Yu X, Yu S, Fan Y (2020) Progress on treatment of MET signaling pathway in non-small cell lung cancer. Int J Clin Oncol 25:1450–1458. https://doi.org/10.1007/s10147-020-01702-0
Zheng X, Zhang G, Li P, Zhang M, Yan X, Zhang X, Yang J, Li H, Liu X, Ma Z et al (2019) Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: successful treatment with gefitinib and crizotinib. Lung Cancer 129:72–74. https://doi.org/10.1016/j.lungcan.2019.01.009
Funding
This study was supported by Major public welfare projects in Henan Province (201300310400)—research and development of new technologies for tumor liquid biopsy and immunotherapy.
Author information
Authors and Affiliations
Contributions
YF, XX, and HX contributed to the study conception and design. RS, ZW, and YZ obtained the clinical data. Data were interpreted by XX and YZ. The manuscript was prepared by YF, HX, YL, and BX. DL and JM critically reviewed and modified the manuscript. The final version of the manuscript was read and approved by all the authors.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest or competing interests.
Ethical approval
The study was approved by the Henan Cancer Hospital (no. 2016056).
Consent to participate
All individual patients have signed the informed consent about usage of resected material.
Consent for publication
The participant has consented to the submission of the study to the journal.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fan, Y., Sun, R., Wang, Z. et al. Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer. J Cancer Res Clin Oncol 149, 1667–1677 (2023). https://doi.org/10.1007/s00432-022-04048-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04048-4